期刊文献+

组蛋白去乙酰化酶抑制剂MS-275对U266细胞增殖的影响及其机制探讨 被引量:2

原文传递
导出
摘要 组蛋白去乙酰化酶(HDAC)抑制剂是一类以HDAC为靶点的小分子化疗药物,能够显著抑制多种肿瘤细胞的增殖,诱导细胞分化和凋亡,在体内外的实验中都表现出显著的抗癌活性。MS-275是属于苯酰胺类的HDAC抑制剂,和其他同类药物相比,它具有很强的特异性和选择性,在部分肿瘤治疗中已经进入了临床试验,并取得了良好的疗效。目前,有关MS-275对多发性骨髓瘤(MM)影响的研究尚未见报道,我们采用人MM细胞系U266细胞作为靶细胞,观察了MS-275对骨髓瘤细胞的影响并对其作用机制进行初步探讨。
出处 《中华血液学杂志》 CAS CSCD 北大核心 2009年第6期416-418,共3页 Chinese Journal of Hematology
基金 基金项目:国家自然科学基金重点项目(30330620)
  • 相关文献

参考文献11

  • 1Acharya MR,Sparreboom A,Venitz J,et al.Rational development of histone deacetylase inhibitors as anticancer agents.Mol Pharmacol,2005,68:917-932.
  • 2Saito A,Yamashita T,Mariko Y,et al.A synthetic inhibitor of histone deacetylase,MS-27-275,with marked in vivo antitumor activity against human tumors.Proc Natl Acad Sci U S A,1999,96:4592-4597.
  • 3Jaboin J,Wild J,Hamidi H,et al.MS-27-275,an inhibitor of histone deacetylase,has marked in vitro and in vivo antitumor activity against pediatric solid tumors.Cancer Res,2002,62:6108-6115.
  • 4Gojo I,Jiemjit A,Trepel JB,et al.Phase 1 and pharmacologic study of MS-275,a histone deacetylase inhibitor,in adults with refractory and relapsed acute leukemias.Blood,2007,109:2781-2790.
  • 5赵名,王生余,候春梅,杜芝燕,徐元基,于晓妉.FK228阻断细胞生存信号通路诱导前列腺癌细胞凋亡[J].中国肿瘤生物治疗杂志,2006,13(2):83-87. 被引量:3
  • 6Richardson PC,,Barlogie B,Berenson J,et al.Extended follow-up of a phase Ⅱ trial in relapsed,refractory multiple myeloma:final time-to-event results from the SUMMIT trial.Cancer,2006,106:1316-1319.
  • 7Ludwig H.Advances in biology and treatment of multiple myeloma.Ann Oncol,2005,16Suppl 2:ii106-112.
  • 8Kim TY,Bang Y J,Robertson KD.Histone deacetylase inhibitors for cancer therapy.Epigenetics,2006,1:14-23.
  • 9Marks PA,Richon VM,Ritkind RA.Histone deacetylase inhibitors:inducers of differentiation or apoptosis of transformed cells.J Natl Cancer Inst,2000,92:1210-1216.
  • 10李薇,王冠军,崔久嵬,陈晓锋,张学敏.丁酸钠诱导NB4细胞凋亡的蛋白质组学研究[J].中华血液学杂志,2006,27(7):436-440. 被引量:4

二级参考文献25

  • 1李薇,王育丽,康丽花,王冠军.丁酸钠上调急性白血病细胞共刺激分子表达及其分子机制研究[J].中华血液学杂志,2005,26(5):265-268. 被引量:4
  • 2Johnstone RW. Histone deacetylase inhibitors: Novel drugs for the treatment of cancer[ J]. Nat Rev Drug Discov, 2002, 1(4) : 287- 299.
  • 3Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells[J]. J Natl Cancer 1nst, 2000, 92(15) : 1210-1216.
  • 4Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates HSP90 acetylation and chaperone-dependent activation of glucocorticoid receptor [ J ]. Mol Cell, 2005, 18 (5) : 601-607.
  • 5Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer [ J ]. J Natl Cancer 1nst, 2001, 93(22) : 1687-1697.
  • 6Culig Z, Steiner H, Bartsch G, et al. Mechanisms of endocrine therapy-responsive and-unresponsive prostate tumors[ J ]. Endocr Relat Cancer, 2005, 12(2) : 229-244.
  • 7Marks PA, Millery T, Richony VM. Histone deacetylases [ J]. Curt Opin Pharmacol, 2003, 3(4) : 344-351.
  • 8Byrd JC, Marcueei G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide ( FK228 ) in chronic lymphocytic leukemia and acute myeloid leukemia[ J ]. Blood, 2005, 105 (3) :959-967.
  • 9Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors[ J ]. J Biol Chem, 2005, 280 (29) : 26729-26734.
  • 10Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class Ⅰ histone deacetylases [ J ]. Cancer Res, 2002, 62 ( 17 ) : 4916-4921.

共引文献5

同被引文献14

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部